APA (7th ed.) Citation

YX, X., YR, B., R, L., YM, P., TT, L., X, Y., . . . S, Y. (2026). A Comprehensive Review of Marketed KRAS Inhibitors and Degraders: Challenges and Opportunities. Medicinal research reviews, 46(4), 810. https://doi.org/10.1002/med.70035

Chicago Style (17th ed.) Citation

YX, Xu, et al. "A Comprehensive Review of Marketed KRAS Inhibitors and Degraders: Challenges and Opportunities." Medicinal Research Reviews 46, no. 4 (2026): 810. https://doi.org/10.1002/med.70035.

MLA (9th ed.) Citation

YX, Xu, et al. "A Comprehensive Review of Marketed KRAS Inhibitors and Degraders: Challenges and Opportunities." Medicinal Research Reviews, vol. 46, no. 4, 2026, p. 810, https://doi.org/10.1002/med.70035.